Avantor (NYSE:AVTR - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.19 by $0.02, FiscalAI reports. Avantor had a negative net margin of 8.42% and a positive return on equity of 9.95%. The firm had revenue of $1.69 billion for the quarter, compared to analysts' expectations of $1.61 billion. During the same period in the previous year, the business earned $0.24 earnings per share. Avantor's revenue for the quarter was up .5% compared to the same quarter last year. Avantor updated its FY 2026 guidance to 0.800-0.830 EPS.
Here are the key takeaways from Avantor's conference call:
- Q2 results exceeded expectations, with revenue of $1.69 billion, adjusted EPS of $0.21, and $152 million in free cash flow excluding restructuring costs.
- VWR Distribution & Services returned to organic growth, up 1.7% year over year, supported by stronger large-customer execution, improved e-commerce performance, and increased pharma and biotech activity.
- Avantor raised its 2026 organic revenue growth outlook to -0.5% to 0.5% and adjusted EPS guidance to $0.80-$0.83, while expecting BMP to return to growth in the second half.
- Strong cash generation enabled $112 million of debt repayment during the quarter and nearly $500 million over the past 12 months; management remains committed to reducing adjusted net leverage below 3 times by year-end.
- BMP organic revenue declined 5.6% in Q2, while consolidated and segment margins faced lower volumes, inflation, freight costs, and unfavorable product mix; education and European demand also remained weaker than desired.
Avantor Trading Up 13.6%
AVTR stock traded up $1.70 during mid-day trading on Wednesday, reaching $14.12. 22,321,042 shares of the stock traded hands, compared to its average volume of 10,680,044. Avantor has a 52-week low of $7.26 and a 52-week high of $15.93. The stock's fifty day moving average is $9.89 and its 200-day moving average is $9.39. The company has a market cap of $9.64 billion, a P/E ratio of -17.36, a P/E/G ratio of 6.55 and a beta of 0.94. The company has a current ratio of 1.76, a quick ratio of 1.17 and a debt-to-equity ratio of 0.68.
Analysts Set New Price Targets
AVTR has been the subject of several research reports. Barclays raised their price objective on shares of Avantor from $7.00 to $8.00 and gave the company an "underweight" rating in a research report on Wednesday, June 24th. Sanford C. Bernstein began coverage on shares of Avantor in a research note on Friday, June 26th. They set a "market perform" rating and a $10.50 target price for the company. Zacks Research upgraded shares of Avantor from a "strong sell" rating to a "hold" rating in a report on Thursday, April 30th. UBS Group set a $8.00 price target on shares of Avantor in a research report on Wednesday, June 24th. Finally, Evercore set a $10.50 price target on Avantor in a report on Monday, July 6th. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus price target of $10.62.
Read Our Latest Report on Avantor
Insider Activity at Avantor
In other news, Director Simon Dingemans purchased 25,000 shares of Avantor stock in a transaction that occurred on Friday, May 1st. The stock was acquired at an average price of $8.14 per share, for a total transaction of $203,500.00. Following the transaction, the director owned 25,000 shares in the company, valued at $203,500. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gregory T. Lucier acquired 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 8th. The stock was purchased at an average cost of $8.32 per share, with a total value of $83,200.00. Following the purchase, the director directly owned 60,000 shares in the company, valued at approximately $499,200. This trade represents a 20.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.28% of the company's stock.
Institutional Trading of Avantor
A number of hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Avantor by 28.1% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,123 shares of the company's stock valued at $49,000 after buying an additional 905 shares in the last quarter. Osaic Holdings Inc. lifted its stake in Avantor by 60.9% in the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company's stock worth $38,000 after acquiring an additional 1,064 shares in the last quarter. UMB Bank n.a. lifted its stake in Avantor by 17.6% in the 4th quarter. UMB Bank n.a. now owns 7,371 shares of the company's stock worth $84,000 after acquiring an additional 1,101 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Avantor by 119.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company's stock worth $29,000 after acquiring an additional 1,189 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its position in Avantor by 0.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 206,386 shares of the company's stock worth $2,576,000 after acquiring an additional 1,279 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.
About Avantor
(
Get Free Report)
Avantor, Inc NYSE: AVTR is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor's offerings are organized across two primary segments.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Avantor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avantor wasn't on the list.
While Avantor currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.